Table 1 Patient characteristics
Number of patients (%) | |
|---|---|
Age | |
≤ 65 years | 9 (41) |
> 65 years | 13 (59) |
Sex | |
Female | 6 (27) |
Male | 16 (73) |
Eastern Co-operative Oncology Group (ECOG) performance status (PS) | |
0 | 11 (50) |
1 | 9 (41) |
2 | 2 (9) |
UICC stage | |
III | 22 (100) |
T descriptor | |
1–2 | 6 (27) |
3–4 | 16 (73) |
N descriptor | |
0–1 | 5 (23) |
2–3 | 17 (77) |
Histology | |
Squamous cell carcinoma (SCC) | 10 (45) |
Adenocarcinoma (AC) | 10 (45) |
Large cell neuroendocrine cancer (LCNEC) | 2 (9) |
Tobacco consumption (PY) | |
0 | 2 (9) |
20–40 | 8 (36) |
> 40 | 12 (55) |
Durvalumab completion rate | |
50% (12 or more cycles) | 15 (68) |
100% (24 cycles) | 8 (36) |
Reason for treatment discontinuation | |
Progress | 8 (50) |
Toxicity | 5 (31) |
Compliance | 1 (6) |
Induction chemotherapy | 7 (32) |
Concurrent chemotherapy | 21 (95) |
PTV > 700 ccm | 9 (41) |
PTV < 700 ccm | 13 (59) |